CD274 and non-small cell lung carcinoma: developed a residual deep network utilizing pre-treatment PET/CT images to predict PD-L1 expression, as well as the durable clinical benefit, progression-free survival (PFS), and overall survival (OS) in advanced-stage NSCLC patients (4).